Biologics

Why have we developed our bio nanoparticle technology?

The biologics industry is expanding rapidly as the potential of biological therapies grows in recognition. The field is also expected to become more versatile as it grows from antibody-focused production to gene and cell therapies, exosomes, fusion proteins and nanotechnology approaches. However, despite their success so far, biologics come with a number of challenges.

Among these is that the production cost of biologics is high. Despite this, increased opportunities for patient centricity exist, including better formulations and different modes of administration to aid drug delivery. Direct nanoforming of biologics is a promising new approach to allow more life-changing large-molecule drugs to reach the market, which was a key driving force behind the development of our proprietary biological technology.

Our technology

Our biological nanoforming technology can deliver large-molecule drug particles as small as 50 nm while retaining biological activity. It’s effectiveness has been demonstrated on proteins in the 6 kDa – 140 kDa range, and it is capable of engineering particle sizes to specific requirements. Our advanced technology can be applied across the biologics field to potentially:

Change delivery routes

Increase uptake

Enable new drug combinations

Tailor release profiles

Enhance drug loading capacity in formulations

Implement lighter infrastructures for drug logistics